Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds (JUVE_BTX)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01269801 |
Recruitment Status :
Completed
First Posted : January 4, 2011
Results First Posted : December 16, 2014
Last Update Posted : December 16, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Wrinkles | Drug: onabotulinumtoxinA Drug: JUVÉDERM | Phase 4 |
-
Compounds:
- BOTOX Cosmetic (onabotulinumtoxinA) for Injection
- JUVEDERM Ultra XC and JUVEDERM Ultra Plus XC Injectable Gel
-
The objectives of this study are:
- To assess physician assessment of efficacy and incremental benefit following BOTOX Cosmetic and Juvederm for the treatment of moderate to severe facial wrinkles and folds;
- To assess patient perceptions of treatment outcomes and incremental benefit following BOTOX Cosmetic and Juvederm for the treatment of moderate to severe facial wrinkles and folds.
-
Investigator and study sites:
- multicenter study
- 5 Sites: 2 in US, 2 in Canada, 1 in EU
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 156 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds |
Study Start Date : | January 2011 |
Actual Primary Completion Date : | September 2011 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Botox Cosmetic
onabotulinumtoxinA for injection
|
Drug: onabotulinumtoxinA
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment. Other Names:
|
Active Comparator: JUVÉDERM
JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
|
Drug: JUVÉDERM
Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions; • Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions. At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment. Other Names:
|
- Efficacy [ Time Frame: Week 4, 8, 12, 24 ]
Assessments at Visits 3,5,6+7 (weeks 4,8,12,24) include:
-Physician Global Aesthetic Improvement Scale (PGAIS). Ratings include no change, improved, much improved, very much improved.
Number of subjects with improvement score for the 5 point PGAIS from baseline to Visit 7.
-Objective Observer Global Aesthetic Improvement Scale Number of subjects with improvement score for the from baseline to Visit 7. Ratings include no change, some improvement, definite improvement, substantial improvement, and complete improvement.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult females or males, aged 25 to 65 years;
- Subjects must be seeking treatment with either BOTOX® or JUVÉDERM injections;
- Subjects must have one or more moderate to severe hyperfunctional facial lines of the upper face (i.e., glabellar lines, lateral canthal lines (crow's feet) or horizontal forehead lines) or moderate to severe nasolabial folds based on the physician observer assessment (0-3 scale);
- Women must either be of non-childbearing potential (i.e., surgically sterilized or post-menopausal) or if of childbearing potential, must not be pregnant (as documented by a negative urine pregnancy test at the baseline examination) or lactating and must be practicing a medically acceptable method of birth control;
- Subjects must be willing and able to provide written informed consent;
- Subjects must be willing and able to follow the procedures outlined in this protocol.
Exclusion Criteria:
- Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control;
- Previous botulinum toxin or semipermanent injectable filler therapy within the past year or any prior history of permanent filler therapy injection;
- Prior cosmetic procedures (i.e., liposuction, etc.) or visible scars that may affect evaluation of response and/or quality of photography;
- Known allergy or sensitivity to any of the study medication or their components;
- Known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies;
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other disease that might interfere with neuromuscular function;
- Concurrent use of aminoglycoside antibiotics that interfere with neuromuscular function;
- Subjects with profound atrophy or excessive weakness of the muscles in the target area(s) of BOTOX injection;
- Subjects with an infection at an injection site or systemic infection (in this case, postpone study entry until one week following recovery);
- Concurrent participation in an investigational drug or device study or participation within 30 days of study start;
- Subjects are not to undergo any additional cosmetic procedures during the study period;
- Subjects are not to change use of any facial products up to 6 months prior to enrollment and during study period;
- Subjects with a history of poor cooperation, non-compliance with medical treatment, or unreliability.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01269801
United States, Colorado | |
About Skin Dermatology | |
Englewood, Colorado, United States, 80113 | |
Canada, Ontario | |
Niagara Falls Dermantology and Skin Care Center | |
Niagara Falls, Ontario, Canada, L2E 7H1 | |
University of Toronto | |
Toronto, Ontario, Canada, M5R3N8 |
Principal Investigator: | Joel L Cohen, MD | AboutSkin Dermatology and DermSurgery, PC |
Responsible Party: | AboutSkin Dermatology, Joel L. Cohen, MD, AboutSkin Dermatology and DermSurgery, PC |
ClinicalTrials.gov Identifier: | NCT01269801 |
Other Study ID Numbers: |
JUVE_BTX-09-01 |
First Posted: | January 4, 2011 Key Record Dates |
Results First Posted: | December 16, 2014 |
Last Update Posted: | December 16, 2014 |
Last Verified: | December 2014 |
BOTOX JUVEDERM Prospective |
Open Label Randomized Crossover Study |
Botulinum Toxins Botulinum Toxins, Type A abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |
Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |